Medical News / AAO 2021 - Veeral Sheth, MD: Identifying Durability, Safety of GB-102 in Wet AMD Treatment

In an interview with HCPLive, Veeral Sheth, MD, Director of Clinical Trials, University Retina, discussed the late breaking findings of the phase 2b ALTISSIMO trial data from the American Academy of Ophthalmology 2021 Meeting. The data from the trial found the mean durability in 1 milligram GB-102 group was 12 months, in patients with wet age-related macular degeneration (wet AMD). Sheth noted the results of this data showed really good durability of the agent. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

According to new phase 3 data presented at the American Academy of Ophthalmology 2021 Meeting, brolucizumab ... read more
Access to US ophthalmology clinical trial sites may differ by region, according to new study findings ... read more
Although there are questions on the rationale behind step therapy, particularly for neovascular (wet) age-related macular ... read more
Over the weekend, important data on avacincaptad pegol treatment in patients from the GATHER1 clinical trial ... read more